Low prevalence of bloodstream infection and high blood culture contamination rates in patients with COVID-19

In the management of COVID-19, knowledge is lacking on the frequency of secondary bacterial infections and on how empirical antibiotic therapy should be used. In the present study, we aimed to compare blood culture (BC) results of a COVID-19 patient cohort with two cohorts of patients without detect...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2020-11, Vol.15 (11), p.e0242533-e0242533
Main Authors: Yu, David, Ininbergs, Karolina, Hedman, Karolina, Giske, Christian G, Strålin, Kristoffer, Özenci, Volkan
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Antibiotics
Bacteremia
Bacterial diseases
Bacterial infections
Biology and Life Sciences
Blood
Blood culture
Blood Culture - methods
Coinfection - diagnosis
Coinfection - epidemiology
Coinfection - virology
Comorbidity
Complications and side effects
Contaminants
Contamination
Coronaviruses
COVID-19
COVID-19 - diagnosis
COVID-19 - epidemiology
COVID-19 - virology
Demographic aspects
Drug therapy
Emergency medical care
False Positive Reactions
Female
Hospitals
Humans
Infections
Laboratories
Male
Management
Medicine
Medicine and Health Sciences
Microorganisms
Middle Aged
Patient outcomes
Patients
Physical Sciences
Prevalence
Retrospective Studies
Reverse Transcriptase Polymerase Chain Reaction
Risk factors
SARS-CoV-2 - genetics
Sepsis - diagnosis
Sepsis - epidemiology
Sepsis - microbiology
Severe acute respiratory syndrome
Severe acute respiratory syndrome coronavirus 2
Statistics
Sweden - epidemiology
Viral infections
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In the management of COVID-19, knowledge is lacking on the frequency of secondary bacterial infections and on how empirical antibiotic therapy should be used. In the present study, we aimed to compare blood culture (BC) results of a COVID-19 patient cohort with two cohorts of patients without detected COVID-19. Using a retrospective cohort study design of patients subjected to BC in six tertiary care hospitals, SARS-CoV-2 positive patients from March 1 to April 30 in 2020 (COVID-19 group) were compared to patients without confirmed SARS-CoV-2 during the same period (control group-2020) and with patients sampled March 1 to April 30 in 2019 (control group-2019). The outcomes studied were proportion of BC positivity, clinically relevant growth, and contaminant growth. In total 15,103 patients and 17,865 BC episodes were studied. Clinically relevant growth was detected in 197/3,027 (6.5%) BC episodes in the COVID-19 group compared to 717/6,663 (10.8%) in control group-2020 (p
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0242533